Insmed (NASDAQ:INSM – Get Free Report) and Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.
Profitability
This table compares Insmed and Palvella Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insmed | -76.94% | -123.94% | -44.30% |
| Palvella Therapeutics | N/A | -47.84% | -38.33% |
Risk and Volatility
Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insmed | $606.42 million | 44.65 | -$1.28 billion | ($4.11) | -30.17 |
| Palvella Therapeutics | N/A | N/A | -$41.72 million | ($4.83) | -31.95 |
Palvella Therapeutics has lower revenue, but higher earnings than Insmed. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
40.1% of Palvella Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Insmed and Palvella Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insmed | 1 | 0 | 22 | 2 | 3.00 |
| Palvella Therapeutics | 1 | 0 | 12 | 2 | 3.00 |
Insmed presently has a consensus target price of $204.91, suggesting a potential upside of 65.28%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 35.53%. Given Insmed’s higher probable upside, research analysts clearly believe Insmed is more favorable than Palvella Therapeutics.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
About Palvella Therapeutics
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
